We have identified a new mammalian protein arginine N-methyltransferase, PRMT5, formerly designated Janus kinase-binding protein 1, that can catalyze the formation of -N G -monomethylarginine and symmetric -N G ,N G -dimethylarginine in a variety of proteins. A hemagglutinin peptide-tagged PRMT5 complex purified from human HeLa cells catalyzes the S-adenosyl-L-[methyl-
Protein arginine methylation has been implicated in the regulation of signal transduction, transcription, and RNA transport (1) (2) (3) (4) (5) . It is an apparently irreversible modification in which the guanidinium group of arginyl residues becomes methylated in a reaction with S-adenosylmethionine (AdoMet) 1 as the methyl donor. Four different types of protein arginine methyltransferase enzymes have been discovered to date. Type I enzymes methylate arginine residues to form -N . Genes encoding enzymes responsible for type I methylation, such as the human PRMT1 and PRMT3 and yeast RMT1, and for type IV methylation, such as yeast RMT2, have already been identified (7) (8) (9) (10) . However, genes encoding species that are capable of the type II or type III methylation have yet to be reported.
The type II enzyme activity has been of much interest because it monomethylates and symmetrically dimethylates myelin basic protein (MBP) at arginine 107 in mammalian species (11) (12) (13) . MBP is a highly conserved protein occurring as a single species in humans and cattle and as several different isoforms in rodents (for reviews, see Refs. 13 and 14) . MBP is a major myelin protein constituting 30% of the total membraneassociated protein (15) . The ratio of unmethylated arginine to -N G -monomethylarginine to symmetric -N G ,N GЈ -dimethylarginine at position 107 varies from species to species, and it has been postulated that older myelin is more highly methylated (16) . Methylation of MBP has been implicated in maintaining the integrity of the myelin sheath. Subacute combined degeneration, a disorder characterized by the degeneration of the myelin sheath, can be induced in mice and monkeys when methylation of MBP is inhibited by exposure to an atmosphere containing 15% nitrous oxide (17, 18) .
Until recently, symmetric dimethylarginine residues have been reported to be found only in myelin basic protein. However, two human Sm small nuclear ribonucleoproteins, D1 and D3, involved in mRNA splicing have recently been discovered to contain both -N G -monomethylarginine and symmetric -N G ,N GЈ -dimethylarginine residues in their C-terminal domains (19) . We have recently found that purified D1 and D3 are methylated in vitro by PRMT5. 2 Although the role of methylation of these two proteins has yet to be determined, the methylation of D1 forms a major linear epitope for anti-Sm auto-antibodies, which are found in people with systemic lupus erythematosus (19) .
In a yeast two-hybrid screen to search for proteins that bind the second polypeptide chain of Janus kinase 2, a protein arginine methyltransferase was identified as Janus kinasebinding protein 1 (JBP1) and shown to catalyze the methylation of MBP and histones H4 and H2A in vitro (20) , as does its yeast homologue Hsl7p (21) . However, the type of methylation of these proteins was not established, although JBP1 showed amino acid sequence similarity to the family of previously identified type I protein arginine methyltransferase catalytic subunits (20) . Recent evidence has been presented that the methyl-accepting substrates are in fact protein arginine residues; however, whether the enzyme catalyzes a type I or type II reaction was not determined (22) . Here we provide evidence that JBP1 can catalyze the formation of -N G -monomethylarginine and symmetric -N G ,N GЈ -dimethylarginine on a variety of substrates in vitro. Therefore, JBP1, now designated PRMT5, represents the first gene encoding a type II protein arginine N-methyltransferase. This PRMT5 polypeptide is a candidate catalytic unit that may be responsible for the modification of myelin basic protein in vivo, the Sm ribonucleoproteins, and additional proteins that require the presence of symmetric dimethylarginine residues.
EXPERIMENTAL PROCEDURES
Purification of GST-GAR-A GST-human fibrillarin (residues 1-148) fusion protein (designated GST-GAR) (8) was overexpressed in Escherichia coli DH5␣ cells (Life Technologies, Inc.) by induction with a final concentration of 0.4 mM isopropyl-␤-D-thiogalactopyranoside. The protein was then purified from extracts by binding to glutathioneSepharose 4B beads (Amersham Pharmacia Biotech) according to the manufacturer's instructions, but in the presence of 100 M phenylmethylsulfonyl fluoride and eluted with 30 mM glutathione, 50 mM Tris-HCl, pH 7.5, 120 mM NaCl, and 2% glycerol. The protein was then desalted on a Sephadex G-25 gel filtration column (13.5-cm column height ϫ 2.5-cm inner diameter; 60-ml bed volume) in 50 mM sodium phosphate, pH 7.5.
Construction of myc-PRMT5 and myc-PRMT5⌬GAGRG-Wild type myc-PRMT5 was cloned as described previously (20) . The mutant myc-PRMT5⌬GAGRG (amino acids 365-369) was constructed by site-directed mutagenesis with phage M13 (23) . The oligonucleotide used to introduce the deletion was 5Ј-CTGATGGTGCTGCCCCTGGTGAACGCTTCCC-3Ј.
In Vitro Labeling of MBP, Histone H2A, and GST-GAR-HA-JBP1 (PRMT5) was immunoprecipitated with anti-HA antibody from the HeLa-HA-SPMT cell line as described previously (20, 21) . 10 -100 g of MBP (Sigma product M1891; purified from bovine brain; lyophilized powder), 10 -100 g of histone H2A (Boehringer Mannheim product 1,034,740; purified from calf thymus), or 2 g of GST-GAR was added to the HA-PRMT5 (immunoprecipitated from 1 ϫ 10 7 HeLa cells/reaction) bound to protein A/G beads, which were then incubated at 37°C for 5 h with 3 l of S-adenosyl-L-[methyl- For myc-tagged proteins, myc-PRMT5 and myc-PRMT5⌬GAGRG were immunoprecipitated with anti-myc antibody from 7.5 ϫ 10 6 COS-1 cells as described previously (20) . 10 g of MBP was added to either myc-PRMT5 or myc-PRMT5⌬GAGRG, which was then incubated at 
. 500 l of citrate sample dilution buffer (0.2 M citrate in Na ϩ containing 2% thiodiglycol and 0.1% phenol, pH 2.2) was added to the hydrolyzed sample before loading onto an amino acid cation exchange column (Beckman AA-15 sulfonated polystyrene beads; 0.9-cm inner diameter ϫ 11-cm column height) equilibrated and eluted with sodium citrate buffer (0.35 M citrate in Na ϩ , pH 5.27) at 1 ml/min at 55°C. 3 H radioactivity was determined by counting a 200-l aliquot of every fraction diluted with 400 l of water in 5 ml of fluor (Safety Solve; Research Products International) three times for 3 min. The unlabeled amino acid standards were analyzed using a ninhydrin assay with 100-l aliquots of every other fraction (5). Chemical Analysis of Methylated Species-A 5-l aliquot of the above-mentioned in vitro reaction for MBP and histone H2A and a 30-l aliquot of the above-mentioned in vitro reaction for GST-GAR were mixed with 11.1 g of bovine serum albumin as a carrier protein and an equal volume of 25% (w/v) trichloroacetic acid in a 6 ϫ 50-mm glass vial and incubated at room temperature for 20 min. The precipitated protein was then centrifuged at 4000 ϫ g for 40 min at 25°C, the supernatant was drawn off and discarded, and the pellets were washed once with an equal volume of acetone at Ϫ20°C. After centrifugation for 20 min as described above, the acetone was discarded, and the pellets were allowed to dry. Acid hydrolysis was carried out on the dried pellet in a Waters Pico-Tag vapor-phase apparatus in vacuo for 20 h at 110°C using 200 l of 6 N HCl, and the hydrolyzed samples were resuspended in 50 l of water for analysis on an amino acid cation exchange column. The column was regenerated with 0.2 N NaOH. Standard amino acids included -N G -monomethylarginine (Sigma product M7033; acetate salt), asymmetric -N G ,N G -dimethylarginine (Sigma product D4268; hydrochloride), and symmetric N G ,N GЈ -dimethylarginine (Sigma product D0390; di-(p-hydroxyazobenzene-pЈ-sulfonate) salt).
Desalting of the Methylated Arginine Derivatives-Pooled fractions from the cation exchange column were loaded onto a Sephadex G-15 column (1.5 cm in diameter and 77 cm in length) at 25°C equilibrated with 0.1 M acetic acid. Fractions (3.5 ml) were collected, and their conductance was determined with a YSI conductance meter model 35. Radioactivity was measured by counting a 200-l aliquot of every fraction diluted with 400 l of water in 5 ml of Safety Solve scintillation fluor (Research Products International). A 100-l aliquot was tested for the nonradioactive standards using the ninhydrin assay as described previously (5) .
RESULTS AND DISCUSSION
To determine the specific products of the methylation reaction catalyzed by PRMT5 (JBP1), HA-tagged PRMT5 was isolated from HeLa cells and incubated with MBP and [ 3 H]AdoMet. Protein reaction products were precipitated with trichloroacetic acid, acid-hydrolyzed to their amino acid components, and fractionated on a high-resolution amino acid analysis cation exchange column along with standards of unlabeled asymmetric -N G ,N G -dimethylarginine and -N G -monomethylarginine, species that are well separated under our conditions (Fig. 1) . We found that most of the radioactivity eluted just ahead of the -N G -monomethylarginine standard at 86 min in a position expected for its tritiated derivative (9, 24, 25) . However, a peak that consistently migrated at about 79 min between the positions of asymmetric -N G ,N G -dimethylarginine and -N G -monomethylarginine standards was also observed. In Fig. 2A , we show that the radioactivity in this second peak at 76 -79 min elutes just prior to the unlabeled symmetric -N G ,N GЈ -dimethylarginine standard, suggesting that PRMT5 may catalyze the formation of the symmetric dimethylarginine derivative. However, ␦-N-monomethylarginine, the product of A had a mobile phase consisting of methanol:14.8 N ammonium hydroxide (3:1, v/v), and B had a mobile phase consisting of n-butanol:acetic acid:water (4:1:1, v/v/v). The sheets were heated at 37°C to evaporate the solvents and then sprayed with ninhydrin (10 mg/ml in acetone). The sheets were incubated again at 37°C until the Ruheman's Purple color appeared. The 3 H radioactivity was determined by dividing the lanes into slices and scraping either the silica or cellulose into scintillation vials. Slices were then diluted with 500 l of water in 5 ml of fluor and counted three times for 3 min.
FIG. 4. HA-PRMT5 can monomethylate arginine at the nitrogen as shown by co-migration with -N
G -monomethylarginine on thin layer chromatography. A desalted pool of fractions 83-86 from Fig. 1 was desalted by gel filtration chromatography as described for fractions 76 -79 in the Fig. 2 legend, and the sample was then concentrated to 1.5 ml in a Speedvac apparatus and analyzed by thin layer chromatography at room temperature on a 20-cm sheet coated with either a layer of silica gel (A) or a layer of cellulose (B) as described in the Fig. 3 legend. the type IV methyltransferase, has also been determined to elute in a similar position on this cation exchange column (25) . To distinguish between these two methylarginine derivatives, we examined their breakdown products upon base treatment. It has previously been shown that when ␦-N-monomethylarginine is treated with base, it forms ␦-N-methylornithine (26), whereas -N G ,N GЈ -dimethylarginine and -N G -monomethylarginine yield methylamine, and -N G ,N G -dimethylarginine yields dimethylamine (27) . We thus treated the material eluting with the symmetric standard with 2 M NaOH at 55°C for 24 h and then re-chromatographed it on the cation exchange column along with unlabeled ␦-N-methylornithine and methylamine standards (Fig. 2B) . No radioactivity was found to coelute with the ␦-N-methylornithine standard. However, radioactivity did co-elute with the methylamine standard, suggesting that the peak in Fig. 1 is also shown to co-elute with the -N G -monomethylarginine standard in these two chromatography methods (Fig. 4) . These results indicate that HA-PRMT5 is capable of catalyzing the formation of -N G ,N GЈ -dimethylarginine and -N G -monomethylarginine in polypeptides. We next asked whether the formation of symmetric dimethylarginine residues occurred only with MBP, or whether the specificity for symmetric dimethylation resided in the enzyme itself. GST-GAR, an artificial polypeptide that has been shown to be an excellent in vitro substrate for type I enzymes that catalyze asymmetric dimethylation (8) , was also found to be radiolabeled in vitro with HA-PRMT5. As shown in Fig. 5 , amino acid analysis of this reaction product clearly demonstrates that arginine residues in GST-GAR are monomethylated (Fig. 5B ) and symmetrically dimethylated (Fig. 5C ), but significantly, these residues are not asymmetrically dimethylated by HA-PRMT5. Additionally, we found that histone H2A, another methyl-accepting substrate of HA-PRMT5 (21), also forms the symmetric -N G ,N GЈ -dimethylarginine and -N Gmonomethylarginine derivatives (data not shown). Our results, therefore, suggest that PRMT5 is capable of specific type II 
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-dimethylarginine) was added to 500 l of citrate sample dilution buffer and fractionated on the amino acid cation exchange column at a flow rate of 1 ml/min. 100-l aliquots of every other fraction were analyzed by the ninhydrin assay. B, purified GST-GAR was methylated in vitro as described under "Experimental Procedures." GST-GAR was then precipitated with trichloroacetic acid, acid-hydrolyzed, and run on the cation exchange column as described in the Fig. 1 legend. C, fractions 67-69 from B were diluted with 14 ml of water and brought to a pH of 2.0 with 6 N HCl. 1.0 mol of the standard -N G ,N GЈ -dimethylarginine was added to the pooled fractions, and the mixture was rerun on the amino acid cation exchange column as described above. (symmetric dimethylation) activity in a substrate-independent fashion.
To verify that the type II activity we see is due to PRMT5 and not an impurity in the enzyme preparation, we constructed myc-tagged mutants of PRMT5 that were transfected into COS-1 cells, and we analyzed the immunoprecipitates for arginine methyltransferase activity. Because the sequence GXGRG of motif I is highly conserved in PRMT5 and its homologues and is important for AdoMet binding (20) , the sequence GAGRG (amino acids 365-369) was deleted to form myc-PRMT5⌬GAGRG. As shown in Fig. 6 , there is a dramatic reduction in the formation of -[
3 H]MMA and [ 3 H]SDMA in the mutated enzyme preparation. The small amount of radioactivity seen in the PRMT5⌬GAGRG mutant preparation may represent co-precipitated endogenous enzymatic activity because a similar amount of radioactivity is seen in a vector-only control of immunoprecipitated COS-1 cell extracts (data not shown). We also constructed a mutant in which the GAAGR sequence of motif I was mutated to GAAAG. When this mutant was analyzed for enzymatic activity, the formation of -[
3 H]MMA and [ 3 H]SDMA was approximately half that of the wild type enzyme (data not shown). In both the deletion and substitution mutants, Western analysis with anti-myc antibodies showed the presence of equivalent amounts of PRMT5 expression.
A MBP-specific arginine methyltransferase activity has been previously purified to "near" homogeneity from calf brain as a large complex (500 kDa) containing two major polypeptides of 75 and 100 kDa (13) . Attempts to dissociate the complex into smaller enzymatically active molecules have failed (13) . The relationship between these polypeptides and the expected 72-kDa PRMT5 (JBP1) polypeptide is unknown at present, although the 75-kDa protein found in the MBP-specific methyltransferase could represent the catalytic PRMT5 polypeptide, and the 100-kDa polypeptide could be an additional subunit that is involved in regulation or substrate specificity. Here we show that PRMT5 purified as a native hemagglutinin-tagged complex from HeLa cells or as a myc-tagged complex from COS-1 cells, which should contain other tightly bound subunits as well, has type II arginine methyltransferase activity. However, it is likely that the 75-kDa protein contains this activity in the absence of additional subunits because it has been demonstrated that the polypeptide itself has methyltransferase activity (22) . 3 We have shown that the PRMT5 complex can methylate MBP, GST-GAR, and histone H2A in vitro, although its physiological methyl-accepting substrate(s) has yet to be deter-3 L. Izotova and S. Pestka, unpublished data. mined. Three potential substrates, MBP and the Sm nuclear ribonucleoproteins D1 and D3, have been shown to be symmetrically dimethylated in vivo (13, 19) . All of these three substrates have a consensus sequence that consists of an arginine residue sandwiched between two glycine residues. This consensus sequence is similar to that found for type I substrates (6). As we show here with GST-GAR, type I substrates can be symmetrically dimethylated in vitro. We have also been able to asymmetrically dimethylate MBP, a type II substrate, with type I enzymes in vitro. 4 These results suggest that it is not the "consensus sequence" or secondary structure of the substrate that is crucial in determining the type of methylation the arginine residue will undergo, but rather the type of specific methyltransferase complex that acts on the methyl acceptor.
The role of PRMT5 in vivo has yet to be determined. PRMT5 was isolated because of its ability to interact with Janus kinase 2 (20) . Homologues of PRMT5 have been identified in Schizosaccharomyces pombe and Saccharomyces cerevisiae. Hsl7, the S. cerevisiae homologue, has been shown to be a negative regulator of the protein kinases Swe1 and Ste20 (28, 29) and exhibits protein methyltransferase activity (21) . Disruption of the gene leads to cell cycle abnormalities and elongated buds (28) . The mammalian PRMT5 gene has been found to partially rescue this phenotype when introduced into S. cerevisiae on a plasmid (21) . Skb1, the S. pombe homologue of Hsl7, interacts with the Shk1 kinase (the S. pombe homologue of Ste20), and disruption of its gene also leads to cell cycle abnormalities (30, 31) . This suggests that PRMT5 may be involved in numerous functions, including cell cycle progression and cellular signaling. We note the connections of enzymes that catalyze posttranslational modifications by phosphorylation and methylation in these systems, and it is possible that both types of reactions interact to achieve metabolic control.
Our demonstration that PRMT5 catalyzes type II activity distinguishes it from all of the known mammalian protein N-arginine methyltransferase homologues that catalyze type I activity. The crystal structures of two type I enzymes, the rat PRMT3 catalytic core (amino acids 201-528) in complex with S-adenosyl-L-homocysteine (32) and RMT1 (amino acids 22-348) (33) , have recently been solved. Both structures exhibit virtually identical core structural features with the predicted site for the arginine methyl-accepting substrate falling within an acidic pocket. Interestingly, all of the PRMTs except Hsl7 and PRMT5 contain an active site methionine residue (amino acid 337 for PRMT3 and amino acid 143 for RMT1) that has been proposed to exclude binding of -MMA in a conformation that would allow its symmetric methylation (32) . However in both PRMT5 (amino acid 446) and Hsl7 (amino acid 474), the residue corresponding to Met-337 is serine. The smaller bulk of the side chain of this residue may now allow for SDMA formation with PRMT5 and possibly Hsl7 (Fig. 7) .
